TongliBio welcomes qualified private investment, strategic partnerships, and out-licensing and co-development opportunities of TongliBio’s programs. We will work with partners to accelerate the clinical development and commercialization of TL-010, both as a single agent, and as a combination therapy for the treatment of various zoonotic diseases that pose a risk for global public health.